Company intelligence / Profile preview

Chaser Therapeutics

Hangzhou, Zhejiang Sheng, Chinachasetherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Chaser Therapeutics is a private Chinese biotech company founded in 2018, focused on developing small molecule drugs primarily targeting neoplasms such as refractory acute myeloid leukemia and triple negative breast cancer. Its lead asset PBSS-1113 targets the deubiquitinases USP25 and USP28 and has reached Phase 1 clinical trials. Another candidate, CT-300, is at preclinical stage for triple negative breast cancer. The company’s therapeutic focus also includes hemic/lymphatic diseases and skin/musculoskeletal diseases. No public information about clinical results or published data was found as of January 2025.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CT1113

Beyond the preview

Go deeper on Chaser Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chaser Therapeutics.

Explore the full profile